Hamza Asumah, MD, MBA, MPH
The Unicorn Delusion
Let’s be honest: Most African healthtech startups won’t become unicorns. They won’t IPO on NYSE. They won’t raise Series D funding at $500M valuation.
And that’s okay.
According to TechCabal Insights’ State of Tech in Africa 2025 report, acquisition is no longer a fallback exit but an intentional strategy in a more disciplined market. M&A activity surged to 67 deals in 2025, a 72% increase from 39 in 2024, making the transformation evident: the ecosystem is transitioning from growth to consolidation.
The question isn’t “Will we be the next Flutterwave?” The question is “What does sustainable success look like for our specific business?”
Why African Healthtech Exits Look Different
Global healthtech exits:
- Large pharma acquiring digital therapeutics for $2-5B
- Insurance companies buying telemedicine for $1-3B
- Big tech entering healthcare through acquisitions
- PE firms rolling up physician practices
African healthtech exits:
- Regional players acquiring to expand geography
- Global companies buying African distribution/presence
- Government/public sector partnerships becoming de facto exits
- Acqui-hires for talent more than technology
- Strategic partnerships that are economically equivalent to exits
The difference: African healthtech market is less mature, valuations are lower, strategic buyers are different, and “success” metrics are adjusted for context.
Who Actually Buys African Healthtech Startups
1. Regional Expansion Plays
Dominant player in one market acquires competitor or complementary service in another market.
Examples:
- MaxAB-Wasoko (Egypt) acquired Fatura to expand B2B commerce and fintech capabilities
- Twiga Foods (Kenya) acquired three distributors to strengthen supply chain
- Chowdeck acquired Mira to integrate POS tools and enhance vendor connections
Why this happens: Easier to buy existing presence than build from scratch. Regulatory approval, local networks, and customer base come with acquisition.
What this means for you: Build strong presence in one market. Make yourself attractive acquisition target for players wanting that market.
2. Global-to-Local Acquisitions
International companies buying African healthtech to gain market access.
Example: hearX (South Africa) merged with US-based Eargo in $100M deal to form LXE Hearing, targeting global hearing loss market.
Why this happens: Global companies want African market access. Building from scratch is slow. Acquiring local player with regulatory approvals, provider networks, and customer trust is faster.
What this means for you: Position as “best way for global company to enter African market X.” Build assets they can’t easily replicate.
3. Acqui-Hires
Buying the team, not necessarily the product.
Why this happens: African tech talent is scarce. Especially talent with healthtech domain expertise, regulatory knowledge, and market understanding. Sometimes cheaper to acquire company than recruit team.
What this means for you: Even if your product hasn’t found product-market fit, exceptional team can still have exit value.
4. Government/Public Sector Integration
Not technically “exit” but economically similar: Long-term contract with government where your solution becomes part of national infrastructure.
Example: DHIS2 implementations across Africa, mHealth4Afrika integration with national health systems.
Why this matters: Once embedded in government systems, you may not have traditional exit but you have sustainable revenue and impact.
5. Strategic Partnerships as Quasi-Exits
Major corporation (pharma, insurance, telco) takes significant equity stake, provides commercial partnership, and gives founders liquidity.
Example: MTN partnering with healthtech startups, taking equity plus providing distribution through mobile network.
Why this works: Founders get liquidity, company gets growth capital and distribution, strategic partner gets innovation and market access.
Realistic Exit Valuations
Let’s discuss numbers nobody wants to say out loud:
Tier 1 exits (exceptional): $50M-$200M
- Proven revenue model
- Multi-country presence
- Strong growth trajectory
- Defensible moats
- Strategic value to acquirer
Tier 2 exits (good): $10M-$50M
- Product-market fit achieved
- Single market dominance or multi-market presence
- Path to profitability
- Acquisition prevents competitor from getting you
Tier 3 exits (acceptable): $2M-$10M
- Revenue traction
- Valuable IP or team
- Fills gap in acquirer’s portfolio
- Return capital to investors + founder liquidity
Tier 4 exits (better than failure): $500K-$2M
- Acqui-hire
- Technology/IP interesting but business struggling
- Founders get salary continuation + small payout
Reality check: Most African healthtech exits are Tier 3-4, not Tier 1-2.
Bio-, med-, and health-deeptech ventures need patient capital, complex regulation, and years of R&D before commercial viability, with returns arriving slowly through licensing deals, pharma acquisitions, or long-term manufacturing contracts—none fitting standard VC math.
Tunisia’s InstaDeep (AI-driven biotech) acquired by BioNTech in 2023 for over €680M was exceptional, signaling that African deep-science companies could help shape global biotech and AI markets. But one major exit doesn’t make an ecosystem; it proves potential while highlighting how rare success remains.
Building for Exit From Day One
This doesn’t mean “flip quickly and cash out.” It means building assets that create exit optionality.
What makes you acquirable:
1. Clean Cap Table
- Not too many investors with blocking rights
- Aligned investor expectations on exit timeline
- Founders own enough equity to care about exit price
- No weird special terms that complicate acquisition
2. Regulatory Clarity
- Approvals in place and transferable
- No pending enforcement actions
- Compliance documentation exists
- Regulatory relationships are positive
3. Financial Transparency
- Clean books
- Real revenue (not just grant funding)
- Understood unit economics
- Documented customer cohorts and retention
4. Defensible Assets
- IP that’s actually valuable (patents, algorithms, data)
- Provider/facility contracts with reasonable terms
- Brand and reputation that transfers with acquisition
- Team willing to stay through transition
5. Integration Readiness
- Systems that can plug into larger organization
- Documentation of processes
- Scalable infrastructure
- Interoperability with standard platforms (FHIR, DHIS2, etc.)
Common Exit Mistakes
Mistake 1: Waiting Too Long
Founder turns down acquisition offer hoping for higher valuation later. Market shifts. No other buyers emerge. Company struggles. Exit opportunity evaporates.
Better: If offer represents good outcome for founders and investors, seriously consider it. Bird in hand beats two in bush.
Mistake 2: Optimizing for Headline Valuation
Taking higher valuation with worse terms (earn-outs, employment lock-ups, clawbacks) creates worse outcome than lower valuation with clean cash.
Better: Optimize for cash to founders and investors, not headline number.
Mistake 3: Not Shopping the Deal
Only talking to one buyer means you have no leverage on price or terms.
Better: Even if you prefer specific buyer, create competitive tension by engaging multiple potential acquirers.
Mistake 4: Poor Integration Planning
Founders don’t think through post-acquisition role, team retention, product roadmap, causing deal to fall apart or value to deteriorate post-close.
Better: Negotiate transition plan, retention packages, and strategic alignment before signing.
Mistake 5: Ignoring Cultural Fit
Acquire company values move fast and break things. Your company values patient safety and protocols. Integration fails because cultures clash.
Better: Assess cultural compatibility during diligence. Walk away if fundamental misalignment.
Strategic Partnerships vs Exits
Sometimes the best “exit” isn’t actually exiting.
Moniepoint’s acquisitions across Africa and Europe were about regulatory access and international reach. Stitch’s purchases of payment infrastructure firms were designed to internalize critical rails rather than depend on third parties. Buying an already-licensed institution can compress years of approvals into a single transaction.
Strategic partnership structures that work:
1. Joint Venture
- You contribute technology/expertise
- Partner contributes distribution/capital
- Both parties own JV entity
- You maintain independence of core business
2. Revenue Sharing Agreements
- Partner gets exclusive distribution rights
- You get revenue share on all sales
- Renewable annually but with long notice period
- Maintains option for future acquisition or full independence
3. Licensing
- Partner pays upfront + royalties
- You retain IP ownership
- They get field-of-use rights
- Potentially multiple partners in different markets
4. Equity Partnership
- Partner takes minority stake (20-40%)
- Provides commercial advantages (distribution, credibility)
- Option for majority acquisition later
- Founders maintain control while getting liquidity
What Investors Think About Exits
Investor perspective: They need exits to return capital to their LPs.
Typical VC fund lifecycle: 10 years. Need portfolio companies to exit in years 5-8 for strong returns.
This creates pressure:
- After Series A, investors start thinking about exit timeline
- After Series B, exit conversations become explicit
- By year 7-8, investors pushing hard for liquidity event
Managing investor expectations:
1. Align on exit philosophy during fundraise
- Are they patient capital or expect fast flip?
- What exit valuations would they consider success?
- Do they have bias toward IPO vs acquisition?
- Who are natural acquirers they’d support approach to?
2. Regular exit scenario planning
- Annually review potential strategic buyers
- Understand what would make you attractive to each
- Build relationships with corp dev teams
- Model exit valuations under different scenarios
3. Don’t surprise investors
- If acquisition discussions start, inform board immediately
- If you’re approached, share with investors even if not interested
- Create competitive process so investors see you maximizing value
The Sustainability Path (Exit Alternative)
Not every company needs to exit.
Some African healthtech companies can build sustainable, profitable businesses that run indefinitely:
- Strong margins
- Recurring revenue
- Manageable competition
- Happy customers
- Fulfilled founders
When this works:
- Markets not attractive to large strategic buyers
- Product/service difficult to scale dramatically
- Founders prefer lifestyle business to exit lottery
- Business generates sufficient cash for comfortable life
Examples:
- Specialty diagnostic clinics in specific cities
- Niche practice management software with loyal customers
- Regional medical supply distributors
What investors think: Most VCs hate this path. They need exits. If you want sustainability over exit, raise from different capital sources (revenue-based financing, patient family offices, impact investors comfortable with dividends).
The Honest Conversation
Ask yourself:
- Do I actually want to exit? Or do I want to build enduring company?
- Am I willing to accept acquisition terms? (Employment lock-up, earn-outs, loss of control)
- Is my business actually acquirable? (Do I have assets someone wants badly enough to pay for?)
- Can I create exit without acquisition? (Secondary sale, dividend recaps, etc.)
- If I don’t exit, what happens? (Sustainable business? Slow death? Need more capital?)
The answers determine your strategy.
What Success Actually Looks Like
For some founders: $10M exit after 5 years is life-changing success. Return capital to investors, change your family’s economic trajectory, start next thing with resources.
For others: Building company that employs 500 people, serves millions of patients, operates for decades is success even without exit.
For others still: Acquisition by global healthcare company, helping them enter African markets, seeing your product reach 10M users is success.
There’s no single definition.
What matters: Are you building toward YOUR definition of success? Or chasing someone else’s?
The Future: What’s Coming
Trends shaping African healthtech exits:
- More consolidation: Fragmented markets will consolidate as dominant players acquire smaller competitors.
- Global acquirers entering: As African markets mature, more international companies will acquire local players.
- Regulatory harmonization: African Medicines Agency and regional regulatory bodies will make multi-country acquisitions more attractive.
- Strategic partnerships first: Expect more “date before marriage” partnerships before full acquisitions.
- Acqui-hires accelerate: As talent competition intensifies, buying teams becomes attractive.
For founders building now: Build optionality. Create valuable assets. Maintain relationships with potential acquirers. But don’t obsess over exit at expense of building great business.
The companies that dominate the next decade won’t necessarily be those measuring success by pilots launched or lives touched in donor reports. They’ll be those whose solutions become operational backbone of African healthcare, embedded in hospital workflows, pharmacy shelves, and insurance claims.
In conclusion, Africa’s healthtech opportunity belongs to those who understand a fundamental truth: on this continent, you don’t merely build the solution; you often have to build the system it runs on.
Some of those builders will exit through acquisition.
Some will build enduring independent companies.
Some will become the acquirers.
All paths are valid. Choose yours consciously.
And remember: Exit is not a dirty word. It’s one possible definition of success in a landscape where success comes in many forms.
The goal isn’t to exit. The goal is to build something valuable enough that exiting becomes an option.
Then you get to choose.
Dr. Hamza Asumah 
Leave a comment